Condition
Late Onset Alzheimer Disease
Total Trials
6
Recruiting
2
Active
2
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Completed3
Recruiting2
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT04838301Phase 2Recruiting
Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
NCT07294586Completed
Exploratory Clinical Study and Validation of Blood Biomarkers for Alzheimer's Disease
NCT00064870Recruiting
Alzheimer's Disease Genetics Study
NCT01222351Not ApplicableCompletedPrimary
Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172
NCT03624842UnknownPrimary
Expanded Access With Trappsol(R) Cyclo (TM) for an Individual Patient With Late Onset Alzheimer's Disease
NCT03349320CompletedPrimary
Response to Donepezil, Drug Plasma Concentration and the CYP2D6 and APOE Genetic Polymorphisms
Showing all 6 trials